Latest Balance Sheet News

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

AF Legal Group reported a robust 9% quarter-on-quarter revenue increase to $7 million in Q3 FY25, marking its fourth consecutive profitable quarter and signaling strong momentum ahead of year-end.

Sovereign Metals has released its March 2025 quarterly report, highlighting an Optimised Prefeasibility Study that confirms the Kasiya Project’s global significance as a low-cost producer of rutile and graphite. The company also reports successful land rehabilitation and robust financial backing ahead of its Definitive Feasibility Study.

Santos Limited's 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction efforts.

Native Mineral Resources Holdings Limited reported a $3.2 million net cash outflow from operations in Q1 2025 but strengthened its balance sheet with a $4.52 million capital raising post-quarter.

Culpeo Minerals reports promising copper-gold-silver results at Vista Montana and secures a strategic option to acquire the Jupiter Copper Project in Chile, while preparing maiden drilling programs across key assets.

MAC Copper Limited reported steady Q1 2025 copper production amid rising costs but strengthened its balance sheet through a significant debt refinancing, positioning itself for a 23% production increase by 2026.

Marmota Limited reports a standout March quarter with a 73% uplift in gold grades at Aurora Tank, bonanza grades at Campfire Bore, and a new high-grade titanium sands discovery at Muckanippie, backed by a $5 million capital raise.

IGO Limited reported a solid Q3 FY25 with robust margins at Greenbushes and improved nickel output at Nova, while Kwinana refinery struggles persist amid strategic shifts in exploration and leadership.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

Renergen Limited reported a near doubling of revenue driven by increased LNG production and prices, yet its loss after tax more than doubled due to commissioning costs and higher depreciation. The company has begun commercial liquid helium sales and is navigating funding challenges and ongoing litigation.